

• BRIEF REPORTS •

Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma

Rinaldo Pellicano, Vincenzo Mazzaferro, Walter Franco Grigioni, Miguel Angel Cutufia, Sharmila Fagoonee, Lorenzo Silengo, Mario Rizzetto, Antonio Ponzetto

Rinaldo Pellicano, Mario Rizzetto, Antonio Ponzetto, Department of Gastro-Hepatology, Ospedale S. Giovanni Battista (Molinette), Torino, Italy

Vincenzo Mazzaferro, Surgery and Liver Transplantation Centre, Istituto Nazionale dei Tumori, Milano, Italy

Walter Franco Grigioni, Department of Pathology, Istituto Addarii, Bologna, Italy

Miguel Angel Cutufia, Sharmila Fagoonee, Lorenzo Silengo, Department of Biology, Biochemistry and Genetics, University of Torino, Italy

Supported by a grant from AIRC (Italian Association for Research on Cancer)

Correspondence to: Professor Antonio Ponzetto, Ambulatorio di Gastroenterologia, Ospedale S Giovanni Battista, Via Chiabrera 34, III piano, 10126 Torino, Italy. ponzetto@inwind.it

Telephone: +39-11-6336255 **Fax:** +39-11-6336250

Received: 2003-08-06 **Accepted:** 2003-10-23

Abstract

AIM: Only a minority of patients carrying a defined viral aetiological agent develop cirrhosis and ultimately hepatocellular carcinoma (HCC), the mechanism underlying the worsening is still undefined. Experimental infection by *Helicobacter hepaticus* in mice causes chronic hepatitis and HCC and recently, more *Helicobacter* species (*Helicobacter* spp.) have been detected in the liver of patients suffering from cholestatic diseases and HCC arising from non-cirrhotic liver. We investigated whether *Helicobacter* spp. sequences could be detected in the liver of patients with cirrhosis and HCC compared to subjects with metastasis to liver from colon cancer.

METHODS: Twenty-three liver samples from patients operated upon for HCC superimposed on hepatitis C virus (HCV)-related cirrhosis and 6 from patients with resected metastases from colorectal cancer, were tested by polymerase chain reaction for presence of genomic 16S rRNA of *Helicobacter* genus using specific primers. DNA sequencing and *cag A* gene analysis were also performed.

RESULTS: Genomic sequences of *Helicobacter* spp. were found in 17 of 20 (85%) liver samples from patients with HCC and in 2 of 6 samples from patients with liver metastasis. In three samples of the first group the result was uncertain. *H pylori* was revealed in 16 out of 17 positive samples and *Helicobacter pullorum* in the other.

CONCLUSION: *Helicobacter* spp., carcinogenic in mice, were found at a higher frequency in the liver of patients with HCV-related cirrhosis and HCC than those in patients without primary liver disease.

Pellicano R, Mazzaferro V, Grigioni WF, Cutufia MA, Fagoonee S, Silengo L, Rizzetto M, Ponzetto A. *Helicobacter* species sequences in liver samples from patients with and without hepatocellular carcinoma. *World J Gastroenterol* 2004; 10(4): 598-601
<http://www.wjgnet.com/1007-9327/10/598.asp>

INTRODUCTION

Hepatocellular carcinoma (HCC) is the fourth cause of cancer death worldwide^[1]. This tumor often follows chronic liver inflammation and longstanding cirrhosis. Cirrhosis of the liver is a diffuse process, characterised by fibrosis and nodule formation, which stems from hepatocellular injury. The cellular necrosis might originate from viral, toxic, metabolic and autoimmune sources^[2]. Moreover, hepatitis B and hepatitis C viruses (HBV and HCV) are well-known etiologic factors for liver cirrhosis, and have been classified by the International Agency for Research on Cancer (IARC) as type I liver carcinogens. Both viruses are highly prevalent in the adult population in Italy^[3,4]. Both viral and host characteristics have been reported to influence the outcome of HBV or HCV infection and the development of cirrhosis, but they do not explain all the epidemiological variations of the disease. For instance, in the case of HCV, the viral genotype 1b^[5] has been repeatedly connected with severity of liver outcome, although in other reports this issue has been debated^[6]. Host characteristics also play an important role in the pathogenesis of liver disease. For example, HLA class II haplotype DR5 has been shown to protect patients from the development of cirrhosis^[7].

Chronic inflammation *per se* is known to be a factor of progression towards cancer^[8], though HCV in itself does not appear to foster a strong inflammatory mechanism^[9]. It is thus not yet clear what factors most influence the outcome of the liver disease. Searching for other noxae has therefore become mandatory. A new infectious agent, *Helicobacter hepaticus* (*H. hepaticus*), that causes chronic active hepatitis and associated liver tumors in A/J Cr mice, has been described by Ward *et al*^[10]. Recently, other *Helicobacter* species (*Helicobacter* spp.), including *Helicobacter pylori* (*H. pylori*), bacteria associated with the pathogenesis of gastric^[11-14] and extradigestive manifestations^[15,16], have been detected in the liver of persons suffering from cholestatic diseases and HCC arising from non-cirrhotic liver^[17,18]. We have previously reported a high frequency of *H. pylori* and *Helicobacter pullorum* (*H. pullorum*) sequences detected by the polymerase chain reaction (PCR), in the liver of patients with cirrhosis and superimposed HCC^[19].

To demonstrate a role of the bacteria as a co-factor in the development of end-stage of liver disease in humans, it is fundamental to evidence whether *Helicobacter* occurs at the same frequency in the liver of patients without primary liver disease. The present study investigated whether *Helicobacter* spp. genomes could be detected in liver specimens from patients without any diagnosis of chronic active hepatitis, cirrhosis or HCC, compared with specimens from HCC patients. Therefore, we analysed liver samples from subjects operated upon for metastasis to the liver from colon cancer and, the presence of *Helicobacter* was assayed by molecular methods.

MATERIALS AND METHODS

Liver samples were obtained during the surgical excision for cure from 23 patients operated upon for HCC superimposed

on hepatitis C virus (HCV)-related cirrhosis and from 6 patients suffering from metastatic cancer to the liver, in whom surgery might obtain remission of the disease. All samples were immediately frozen in liquid nitrogen and stored at -80°C prior to testing. The architectural pattern and histologic grade of tumor differentiation of HCC were recorded in accordance with World Health Organisation (WHO) proposals^[20]. HCV infection was demonstrated by means of an ELISA (AxSYM System, Abbott Diagnostics) and an RIBA (RIBA II, LIA, HCV3, Sorin, Saluggia, Italy), and confirmed through detection of circulating HCV-RNA in a PCR.

DNA extraction from liver tissues

Approximately 3 mm³ of tissue was cut and incubated with 0.4 mg/ml proteinase K (Sigma, St Louis) in 0.5 ml extraction buffer (10 mM Tris-HCl, pH 7.5; 1 mM ethylene diamine tetra acetate or EDTA, pH 8; 0.25M sodium chloride; 0.2% sodium dodecyl sulphate or SDS) at 56°C on an agitator until total tissue digestion, the proteinase K was inactivated by boiling it for 10 min. The mixture was centrifuged at 14 000 rpm (Eppendorf centrifuge 5415 C) at room temperature, and to the supernatant, 1 volume of phenol/chloroform (1:1 ratio, equilibrated with 0.1 M phosphate buffered saline, pH 7.5) was added. After vortexed and centrifuged at 14 000 rpm, the aqueous phase was precipitated with 2 volumes of 100% ethanol containing 10% volume of 3M sodium acetate, pH 4.8 at -80°C for 20 min or at -20°C overnight. After two washes with 75% ethanol, the pellet was dried and resuspended in 300 μl TE buffer (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, pH 8) for further use.

Nested-PCR

Amplification of 16S rRNA gene Samples were amplified by *Helicobacter* genus-specific 16S ribosomal RNA (16S rRNA) primers (designated Heli, Table 1) that could identify genomic sequences of 26 species of *Helicobacter*.

First amplification step Genomic DNA was amplified in a total volume of 50 μl containing PCR buffer (1X), 200 μM dNTP, 4 mM Mg²⁺, 0.2 μM primers (Heli-nest-S and Heli-nest-R, Table 1), 1 U *Taq* DNA polymerase (GibcoBRL, USA) and 1 μg of total DNA. The reaction mixture was initially denatured for 2 min at 94°C then amplified for 35 cycles as follows: denaturation for 30 s at 94°C , primer annealing for 30 s at 55°C and extension for 1.5 min at 72°C . A final extension step was done for 5 min at 72°C (Thermocycler HYBAID-OmniGene TR3 5M2-UK). An amplification product of 1 300 bp by the forward and reverse primers was expected. **Second amplification step** PCR was repeated as above with minor alterations: 1 μl of amplicon was used from the first amplification step, the annealing temperature was brought to 60°C , extension time lasted 30 s for 35 cycles and Heli-R/Heli-S primers (Table 1) were used. The expected size of the amplicon was 480 bp.

Amplification of *cag A* gene

Samples generating a positive result from the Nested-PCR were subsequently analysed with a different pair of primers (CagA, Table 1). The CagA-1 and CagA-2 primers used (Table 1) amplified a 290 bp product from the 128 KDa Cag A protein, typical of *H. pylori*^[21]. Fifty microliter of reaction mixture was prepared containing PCR buffer (1X), 2 mM of Mg²⁺, 200 μM dNTP, 0.2 μM primers, 1 U of *Taq* DNA polymerase and 1 μg of DNA. Amplification consisted of an initial denaturation for 2 min at 94°C then amplified for 50 cycles as follows: for 30 s at 94°C , for 30 s at 61°C and for 1 min at 72°C . Extension was continued for another cycle for 5 min at 72°C . The PCR products were analysed on a 2% agarose gel. Positive

and negative controls were included. VCS Hae III and VCS Hinf I were used as DNA size standard for amplification with Heli primers and Cag A primers, respectively.

Table 1 Primers used for amplification of 16S rRNA and *cag A* genes

Primers	Sequences 5' → 3'
Heli-nest-S	5' att agt ggc gca cgg gtg agt aa 3'
Heli-nest-R	5' ttt agc atc ccg act taa ggc 3'
Heli-S	5' gaa cct tac cta ggc ttg aca ttg 3'
Heli-R	5' ggt gag tac aag acc cgg gaa 3'
CagA-1	5' ata atg cta aat tag aca act tga gcg a 3'
CagA-2	5' tta gaa taa tca aca aac atc acg cca t 3'

Southern blot hybridisation

For this purpose, 10 μl of the amplified DNA samples was electrophoresed on a 1% agarose gel. The samples were then transferred to nylon hybond N+ membrane (Amersham Pharmacia Biotech Inc., UK) treated with denaturing agent (0.5 M sodium hydroxide, 1.5 M sodium chloride). The membrane was then neutralised with 5X SSC (0.75M sodium chloride and 0.075M sodium acetate) for 1 min. The membrane was prehybridised in buffer (5X SSPE (0.6 M NaCl, 40 mM NaH₂PO₄, 4 mM EDTA), 0.5% SDS, 5X Denhardt's solution, 0.02 mg/ml Salmon sperm) at 65°C for 4 h. A freshly denatured probe, amplified from *H. pullorum* DNA and labelled with P³²(Rediprime™ II, random labelling system, Amersham Pharmacia Biotech Inc., UK) according to the manufacturer's instructions, was purified using Microspin™ S-400 (HR Columns, Amersham Pharmacia Biotech Inc., New Jersey, USA). Hybridisation was performed overnight at 65°C in hybridisation solution containing blocking reagent (5X SSPE, 0.5% SDS, 5X Denhardt's solution) and the DNA probe. The nylon membrane was then washed in 2X SSC, 0.1% SDS for 15 min at RT, 2X SSC, 0.1% SDS for 15 min at 65°C , 1X SSC, 0.1% SDS for 15 min at 65°C and 0.5X SSC, 0.1% SDS for 10 min at 65°C . The bound probes were finally detected by autoradiography after 4 h at RT (Kodak scientific imaging film, X-OMAT/AR, Rochester, New York).

Sequencing of DNA

PCR-amplified *Helicobacter* genus-specific PCR products were run on a 2% agarose gel, purified using the QIAquick gel extraction kit (QIAGEN, Germany) and sequence analysis was performed with an Applied Biosystems DNA sequencer (Perkin-Elmer, Applied Biosystems, Warrington, Great Britain) following the procedure of the manufacturer, using the ABI PRISM 310 big dye terminator cycle sequencing kit. The sequences were entered, aligned and compared with known *Helicobacter* species using the BLAST programme (Genetics Computer Group, Madison, Wis.).

RESULTS

Screening for *Helicobacter* genus

We found DNA sequences typical of *Helicobacter* spp. in 17 of 20 (85%) livers from patients operated for HCC using *Helicobacter* genus-specific 16S rRNA primers. Three samples (15%) were negative, while in the remaining 3 out of 23, the results were uncertain. Two of 6 liver samples obtained from 6 patients whose livers were resected for metastasis due to colon cancer, contained sequences typical of *Helicobacter* spp.

The 480 bp product obtained in the second round of the nested-PCR with Heli primers is shown in Figure 1. The liver samples with a positive result by this method were all positive

by Southern blot hybridisation using P³²-labelled probe generated from *H. pullorum* DNA (data not shown). These results confirmed the presence of *Helicobacter* gene sequences in the liver samples analysed from patients with cirrhosis and HCC.




Figure 1 Agarose gel (2%) showing PCR products obtained with *Helicobacter* genus-specific 16S ribosomal RNA primers. Lane 1 negative control (DEPC-treated water). Lanes 3 and 4 liver samples from patients with metastatic liver cancer. Lanes 2, 5, 6, 7, 8 and 9 positive liver samples. Lane 10 positive control (*H. hepaticus* DNA). MW molecular-weight marker (VCS Hae III).

Type I *H. pylori* identification

The patients whose liver samples gave a signal typical for *Helicobacter* genus with Heli primers (Table 1), were analysed with primers specific for the amplification of a 290 bp stretch of the *cag A* gene^[21]. The bands amplified corresponded to the expected size (Figure 2).

Overall, 16 out of 17 (94%) liver tissues from patients who were positive when tested for *Helicobacter* genus, were also found to be positive when tested for the presence of a sequence that was typical only for type I *Helicobacter pylori*, i.e., the *cag A* gene.




Figure 2 Analysis of *cagA*-specific PCR products from *Helicobacter* genus positive liver samples of patients with cirrhosis and HCC. The 290 bp fragments were examined on 2% agarose gel electrophoresis. Lane 1 negative control (DEPC-treated water). Lanes 2 to 6 *Helicobacter* genus positive liver samples. Lanes 7 and 8 positive controls (*cagA*-cDNA). MW molecular-weight marker (VCS Hinf I). Lanes 2, 3, 5, and 6 positive for amplified *cagA* fragment. Lane 4 negative for *cagA*.

Presence of *H. pylori* confirmed after DNA sequencing

The *Helicobacter* positive DNA fragments were sequenced. Comparison of DNA sequences of the genomic 16S rRNA amplicons with those of known *Helicobacter* spp. was performed using sequence alignment with the BLAST programme. The presence of *H. pylori* and *H. pullorum* sequences was thus confirmed in these liver samples.

DISCUSSION

Despite the profound impact of HCC on human health worldwide^[22], its pathogenesis remains uncertain. Thanks to the availability of very efficient vaccines that could prevent

HBV infection, WHO has sought to eradicate HBV infection and hence its long-term consequences such as HCC. However, in most industrialised countries, it has been shown that neither HBV nor *Schistosoma* infections play a major role in the development of HCC, instead, the majority of patients carry HCV. This virus does not integrate into host DNA, and it is likely that the mechanism of carcinogenesis differs from that of HBV. Therefore, the need to clarify the pathogenic mechanisms by which HCV may lead to liver cancer has become of prime importance.

Since the currently known risk factors cannot explain all aspects of its progression to HCC, other causal mechanisms should be explored^[23]. From an epidemiological aspect, several studies have evidenced a high seroprevalence of *H. pylori* among cirrhotic subjects^[24-26], but these data have not been ubiquitarily confirmed^[27]. Part of these differences might be explained by geographical and clinical differences in the population studied and the study-design^[23]. Experimentally, Ward *et al.* have fulfilled Koch's postulates as far as the association of *H. hepaticus* with chronic active hepatitis and HCC in mice was concerned^[10]. Whether *Helicobacter* spp. could act as a cofactor in the progression towards cirrhosis and carcinogenesis in humans with viral hepatitis, is still under review^[23].

Chronic hepatitis is an inflammatory disease and each inflammatory process is characterised by increased levels of pro-inflammatory cytokines such as interleukins 1, 6 (IL-1, IL-6), tumor necrosis factor (TNF) and by the presence of lympho-mono cellular infiltrate and lymphoid follicle formation^[28]. Viruses, such as HCV, are only capable of limited inflammation, due to shedding IL-1 receptor in circulation, thereby limiting the possibility of IL-1 binding to cellular receptors^[23]. *Helicobacters*, on the other hand, are strong inducers of the inflammatory cascade^[29], infection with them could lead to the accumulation of extraordinary number of lymphocytes and polymorphonuclear cells in the infected tissue. IL-1 gene cluster polymorphisms, thought to enhance IL-1 β production, confer an increased risk of cancer in patients infected with *H. pylori*^[30]. Furthermore, Meyer-ter-Vehn *et al.* have recently shown that strains of Cag-A-expressing *H. pylori* could activate the ERK/MAP kinase cascade, resulting in Elk-1 phosphorylation and increased *c-fos* transcription. Proto-oncogene activation might represent a crucial step in the pathomechanism of *H. pylori*-induced neoplasia. It has been shown that several *Helicobacter* spp. could also secrete a liver-specific toxin that causes hepatocyte necrosis in cell culture, and might therefore also be involved in damaging liver parenchyma *in vivo*.

The possibility that *Helicobacter* spp. could infect the biliary tract and the liver of humans has been reported by several studies in different settings. Fox *et al.* have shown the presence of *Helicobacter* spp. in the bile of Chileans with chronic cholecystitis. Avenaud and coworkers have demonstrated by PCR the presence of genomic sequences of *Helicobacter* spp. in the liver of 8 patients with HCC without primary diagnosis of cirrhosis, a further analysis by sequencing revealed that these species were *H. pylori* and *Helicobacter felis*^[18]. Similarly, we have reported the presence of the *cagA* gene sequences obtained from the liver tissue of cirrhotic patients with HCC^[19]. Furthermore, Nilsson *et al.* have identified *H. pylori* and *Helicobacter* spp. in human liver samples from patients suffering from primary sclerosing cholangitis and primary biliary cirrhosis^[17] and recently in liver samples of patients with cholangiocarcinomas or HCC.

Of great interest is the fact that the gene sequence obtained from positive *Helicobacter* spp. specific 16S rRNA PCR was usually most analogous to *H. pylori*. This encourages the speculation that the presence of *Helicobacter* DNA in human

liver tissue might reflect the transport of *H pylori* of gastric origin or its DNA to the liver. Studies have also indicated that intestinal *Helicobacter* might be implicated in hepatobiliary disease^[17]. Recently, for the first time, the culture of a *Helicobacter* strain from the human liver has been described. So far, few studies have been reported regarding the presence of *Helicobacter* spp. genomes in liver tissues from patients not suffering from primary chronic liver diseases.

We now report the infrequent presence of genomic sequences of *H pylori* in liver parenchyma of patients operated upon for metastasis to the liver arising from colon cancer. In contrast, the presence of genome of *Helicobacter* spp. was found with a higher frequency in the liver from patients with HCV-related cirrhosis and HCC. This finding lends support to the hypothesis that co-infection with *H pylori* or *Helicobacter* spp. might amplify the chronic inflammation of the parenchyma, thereby leading to cirrhosis and HCC^[23]. To date, we do not know whether bacterial infection of the liver could play a pathogenic role in the development of human HCC, analogous to what has been observed in the mouse model, and the question awaits clarification.

ACKNOWLEDGEMENT

We thank Dr. J. Stanley for providing *Helicobacter pullorum* DNA.

REFERENCES

- Parkin DM**, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. *Int J Cancer* 1999; **80**: 827-841
- Sherlock S**, Dooley J. Diseases of the liver and biliary system. 10th Edition. Oxford: *Blackwell Scientific Publications* 1997
- Maio G**, D' Argenio P, Stroffolini T, Bozza A, Sacco L, Tosti ME, Intorcchia M, Fossi E, D' Alessio G, Anesti Kondili A, Rapicetta M, Mele A and the collaborating group. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. *J Hepatol* 2000; **33**: 116-120
- Guadagnino V**, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, Caroleo B, Costa C, Griffo G, Loiacono L, Pisani V, Foca A, Piazza M. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. *Hepatology* 1997; **26**: 1006-1011
- Silini E**, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, Iamoni G, Tinelli C, Mondelli MU, Ideo G. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. *Gastroenterology* 1996; **111**: 199-205
- Wiese M**, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. *Hepatology* 2000; **32**: 91-96
- Peano G**, Menardi G, Ponzetto A, Fenoglio L. HLA-DR5. A genetic factor influencing the outcome of hepatitis C virus infection? *Arch Intern Med* 1994; **154**: 2733-2736
- Cassell GH**. Infectious causes of chronic inflammatory diseases and cancer. *Emerging Infect Dis* 1998; **4**: 475-487
- Mosnier JF**, Scoazec JY, Marcellin P, Degott C, Behhamou JP, Feldmann G. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. *Gastroenterology* 1994; **107**: 1457-1468
- Ward JM**, Fox JG, Anver MR, Haines DC, George CV, Collins MJ, Gorelick PL, Nagashima K, Gonda MA, Gilden RV, Tully JG, Russell RJ, Benveniste RE, Paster BJ, Dewhirst FE, Donovan JC, Anderson LM, Rice JM. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel *Helicobacter* species. *J Natl Cancer Inst* 1994; **86**: 1222-1227
- Bulent K**, Murat A, Esin A, Fatih K, MMMurat H, Hakan H, Melih K, Mehmet A, Bulent Y, Fatih H. Association of *CagA* and *VacA* presence with ulcer and non-ulcer dyspepsia in a Turkish population. *World J Gastroenterol* 2003; **9**: 1580-1583
- Palmas F**, Pellicano R, Massimetti E, Berrutti M, Fagoonee S, Rizzetto M. Eradication of *Helicobacter pylori* infection with proton pump inhibitor-based triple therapy. A randomised study. *Panminerva Med* 2002; **44**: 145-147
- Testino G**, Cornaggia M, De Iaco F. *Helicobacter pylori* influence on gastric acid secretion in duodenal ulcer patients diagnosed for the first time. *Panminerva Med* 2002; **44**: 19-22
- Li S**, Lu AP, Zhang L, Li YD. Anti-*Helicobacter pylori* immunoglobulin G (IgG) and IgA antibody responses and the value of clinical presentations in diagnosis of *H pylori* infection in patients with precancerous lesions. *World J Gastroenterol* 2003; **9**: 755-758
- Roussos A**, Philippou N, Gourgoulialis KI. *Helicobacter pylori* infection and respiratory diseases: a review. *World J Gastroenterol* 2003; **9**: 5-8
- Yakoob J**, Jafri W, Abid S. *Helicobacter pylori* infection and micronutrient deficiencies. *World J Gastroenterol* 2003; **9**: 2137-2139
- Nilsson H**, Taneera J, Castedal M, Glatz E, Olsson R, Wadstrom T. Identification of *Helicobacter pylori* and *Helicobacter* species by PCR, hybridization and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. *J Clin Microbiol* 2000; **38**: 1072-1076
- Avenaud P**, Marais A, Monteiro L, Lebail B, Biouclat Sage P, Balabaud C, Mégraud F. Detection of *Helicobacter* species in the liver of patients with and without primary liver carcinoma. *Cancer* 2000; **89**: 1431-1439
- Ponzetto A**, Pellicano R, Leone N, Cutufia MA, Turrini F, Grigioni WF, D' Errico A, Mortimer P, Rizzetto M, Silengo L. *Helicobacter pylori* infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? *Med Hypotheses* 2000; **54**: 275-277
- Ishak KG**, Anthony PP, Sobin LH. Histological typing of tumors of the liver. World Health Organization. New York : *Springer Verlag* 1994
- Covacci A**, Censini S, Bugnoli M, Petracca R, Burrone D, Macchia G, Massone A, Papini E, Xiang Z, Figura N, Rappuoli R. Molecular characterization of the 128 kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci U S A* 1993; **90**: 5791-5795
- Sun HC**, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma-A literature review of randomized control trials. *World J Gastroenterol* 2003; **9**: 635-640
- Fagoonee S**, Pellicano R, Rizzetto M, Ponzetto A. The journey from hepatitis to hepatocellular carcinoma: bridging role of *Helicobacter* species. *Panminerva Med* 2001; **43**: 279-282
- Siringo S**, Vaira D, Menegatti M, Piscaglia F, Sofia S, Gaetani M, Miglioli M, Corinaldesi R, Bolondi L. High prevalence of *Helicobacter pylori* in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. *Dig Dis Sci* 1997; **42**: 2024-2030
- Spinzi G**, Pellicano R, Minoli G, Terreni N, Cutufia M, Fagoonee S, Rizzetto M, Ponzetto A. *Helicobacter pylori* seroprevalence in hepatitis C virus positive patients with cirrhosis: the Como cross-sectional study. *Panminerva Med* 2001; **43**: 85-87
- Pellicano R**, Leone N, Berrutti M, Cutufia MA, Fiorentino M, Rizzetto M, Ponzetto A. *Helicobacter pylori* seroprevalence in hepatitis C virus positive patients with cirrhosis. *J Hepatol* 2000; **33**: 648-650
- Chen JJ**, Chang-Chien CS, Tai DI, Chiou SS, Lee CM, Kuo CH. Role of *Helicobacter pylori* in cirrhotic patients with peptic ulcer. *Dig Dis Sci* 1994; **39**: 1565-1568
- Balkwill F**, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; **357**: 539-545
- Crabtree J**. Cytokine responses to *Helicobacter pylori* -induced infection. In: Riecken EO, Zeitz M, Stallmach A, Heise W editors. Malignancy and chronic inflammation in the gastro-intestinal tract: new concepts. Lancaster: *Kluwer Academic Publishers* 1995: 25-36
- El-Omar EM**, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraument JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; **404**: 398-402